Aptorum Group Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG6096M1226
USD
1.40
0.1 (7.69%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

60.59 k

Shareholding (Dec 2024)

FII

0.48%

Held by 3 FIIs

DII

98.13%

Held by 1 DIIs

Promoter

0.00%

What does Aptorum Group Ltd. do?

22-Jun-2025

Aptorum Group Ltd. is a pharmaceutical company focused on developing treatments for infectious diseases and oncology, with a market capitalization of $7.79 million. Key financial metrics include a debt equity ratio of 0.12 and a return on equity of -14.26%.

Overview:<BR>Aptorum Group Ltd. is a pharmaceutical company focused on the discovery, development, and commercialization of therapeutic assets to treat diseases, particularly in the infectious diseases and oncology sectors, and operates within the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Market cap: USD 7.79 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.12<BR>Return on Equity: -14.26%<BR>Price to Book: 0.37<BR><BR>Contact Details:<BR>Address: 17 Hanover Square, LONDON None: W1S 1BN<BR>Tel: 44 20 80929299<BR>Fax: 44 20 39288277<BR>Website: http://www.aptorumgroup.com/

Read More

Who are in the management team of Aptorum Group Ltd.?

22-Jun-2025

As of March 2022, the management team of Aptorum Group Ltd. includes President and Executive Director Mr. Darren Lui, CEO and Founder Mr. Ian Huen, Chief Medical Officer Dr. Clark Cheng, and several Non-Executive Independent Directors: Mr. Douglas Arner, Mr. Charles Bathurst, Dr. Mirko Scherer, and Dr. Justin Wu.

As of March 2022, the management team of Aptorum Group Ltd. includes the following members:<BR><BR>- Mr. Darren Lui, who serves as the President and Executive Director.<BR>- Mr. Ian Huen, the Chief Executive Officer, Founder, and Executive Director.<BR>- Dr. Clark Cheng, who holds the position of Chief Medical Officer and Executive Director.<BR>- Mr. Douglas Arner, a Non-Executive Independent Director.<BR>- Mr. Charles Bathurst, also a Non-Executive Independent Director.<BR>- Dr. Mirko Scherer, another Non-Executive Independent Director.<BR>- Dr. Justin Wu, who is a Non-Executive Independent Director.<BR><BR>This team oversees the strategic direction and management of the company.

Read More

Is Aptorum Group Ltd. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is not enough technical data to assess the current stance of Aptorum Group Ltd.

As of 1 November 2023, there is insufficient technical data available to determine the current stance for Aptorum Group Ltd.

Read More

Is Aptorum Group Ltd. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Aptorum Group Ltd. is considered overvalued due to its high price-to-earnings and price-to-book ratios compared to peers, and its stock performance has not exceeded the Sensex, indicating a disconnect from its underlying fundamentals.

As of 15 October 2023, Aptorum Group Ltd. moved from fair to overvalued. The company currently shows a price-to-earnings ratio of 25.4, a price-to-book ratio of 5.1, and a debt-to-equity ratio of 1.2. Compared to its peers, Athersys Inc. has a price-to-earnings ratio of 15.8, while Sorrento Therapeutics Inc. stands at 12.3, indicating that Aptorum is trading at a premium relative to its industry counterparts.<BR><BR>Given the high valuation ratios and the comparison with peers, Aptorum Group Ltd. appears to be overvalued. Recent stock performance has not outpaced the Sensex, further supporting the conclusion that the current market price does not reflect the underlying fundamentals.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 12 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.12

stock-summary
Return on Equity

-14.26%

stock-summary
Price to Book

0.58

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.13%
0%
-18.13%
6 Months
35.27%
0%
35.27%
1 Year
92.31%
0%
92.31%
2 Years
-16.67%
0%
-16.67%
3 Years
-76.66%
0%
-76.66%
4 Years
-91.57%
0%
-91.57%
5 Years
-94.29%
0%
-94.29%

Aptorum Group Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-14.40%
EBIT Growth (5y)
12.36%
EBIT to Interest (avg)
-11.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.74%
ROCE (avg)
0
ROE (avg)
2.51%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.36
EV to EBIT
-2.68
EV to EBITDA
-2.88
EV to Capital Employed
0.43
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-16.03%
ROE (Latest)
-14.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (1.39%)

Foreign Institutions

Held by 3 Foreign Institutions (0.48%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Aptorum Group Ltd."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -69.23% vs -13.33% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 62.61% vs 57.56% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "1.30",
          "chgp": "-69.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.40",
          "val2": "-16.30",
          "chgp": "42.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-11.50",
          "chgp": "62.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-24,394.70%",
          "val2": "-13,511.30%",
          "chgp": "-1,088.34%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.40
1.30
-69.23%
Operating Profit (PBDIT) excl Other Income
-9.40
-16.30
42.33%
Interest
0.10
0.00
Exceptional Items
-0.20
0.00
Consolidate Net Profit
-4.30
-11.50
62.61%
Operating Profit Margin (Excl OI)
-24,394.70%
-13,511.30%
-1,088.34%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -69.23% vs -13.33% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 62.61% vs 57.56% in Dec 2022

stock-summaryCompany CV
About Aptorum Group Ltd. stock-summary
stock-summary
Aptorum Group Ltd.
Pharmaceuticals & Biotechnology
Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases, particularly infectious diseases and cancers (including orphan oncology indications). Through the establishment of drug discovery platforms, it enables the discovery of new therapeutics assets through systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to this, the Company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.
Company Coordinates stock-summary
Company Details
17 Hanover Square , LONDON None : W1S 1BN
stock-summary
Tel: 44 20 80929299
stock-summary
Registrar Details